Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded by StockNews.com to “Sell”
StockNews.com downgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a hold rating to a sell rating in a report published on Monday morning. Several other analysts also recently commented on LGND. Royal Bank of Canada raised their price objective on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the company an […]
StockNews.com downgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a hold rating to a sell rating in a report published on Monday morning. Several other analysts also recently commented on LGND. Royal Bank of Canada raised their price objective on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the company an […]
